Global Consortium for Biomarker Standardization

At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: Alzheimer's Association
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Alzheimer's Disease
  • Location: North America


The Alzheimer’s Association has established the Global Consortium for Biomarker Standardization to gather key researchers, clinicians, and industry, regulatory, and government leaders in Alzheimer’s disease (AD) to achieve consensus on the best ways to standardize and validate biomarker tests for use in clinical practices around the world.


The Consortium will continue to grow and expand as the field identifies novel technologies and techniques for diagnosis of AD. To date, projects are addressing the following:


July 7, 2011: Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. Alzheimer’s & Dementia. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers.


Points of Contact

Maria C. Carrillo, Ph.D.
Vice President, Medical & Scientific Relations
Alzheimer's Association

Sponsors & Partners

Alzheimer's Association

Last Updated: 04/18/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.